E. Haaksma

发表

Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker

C. Klein, G. Bader, F. Solca, 2012, Journal of Pharmacology and Experimental Therapeutics.

GRID/CPCA: a new computational tool to design selective ligands.

Mika A. Kastenholz, T. Fox, M. Pastor, 2000, Journal of medicinal chemistry.

Serine and threonine residues bend alpha-helices in the chi(1) = g(-) conformation.

L. Pardo, J. Ballesteros, X. Deupí, 2000, Biophysical journal.

Ensemble Rule‐Based Classification of Substrates of the Human ABC‐Transporter ABCB1 Using Simple Physicochemical Descriptors

Gerhard F Ecker, Peter Ettmayer, G. Ecker, 2010, Molecular informatics.

Predicting Ligand Interactions with ABC Transporters in ADME

G. Ecker, P. Ettmayer, O. Kraemer, 2009, Chemistry & biodiversity.

In silico prediction of substrate properties for ABC-multidrug transporters

Gerhard F. Ecker, Eric E. J. Haaksma, Michael A. Demel, 2008 .

Title: Target Binding Properties and Cellular Activity of Afatinib (bibw 2992), an Irreversible

C. Klein, G. Bader, F. Solca, 2012 .

Histamine receptors: subclasses and specific ligands.

R. Leurs, H. Timmerman, E. Haaksma, 1990, Pharmacology & therapeutics.

Heterocyclic thrombin inhibitors. Part 1: design and synthesis of amidino-phenoxy quinoline derivatives.

H. Nar, E. Haaksma, J. Stassen, 2003, Bioorganic & Medicinal Chemistry Letters.

Heterocyclic Thrombin Inhibitors. Part 1. Design and Synthesis of Amidino-Phenoxy Quinoline Derivatives.

H. Nar, E. Haaksma, J. Stassen, 2003 .

Studies on the active molecular species of the H2 receptor antagonists cimetidine and mifentidine.

A. Bast, H. Timmerman, E. Haaksma, 1987, Journal of medicinal chemistry.

Serine and Threonine Residues Bend α-Helices in the χ1 = g− Conformation

Leonardo Pardo, Eric E. J. Haaksma, Xavier Deupi, 2000 .

BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis

G. Adolf, N. Kraut, P. Garin‐Chesa, 2015, Molecular Cancer Therapeutics.

The effect of a protein environment on the proposed activation mechanism of the histamine H2-receptor

Harel Weinstein, Eric E. J. Haaksma, H. Weinstein, 1991 .

A theoretical study concerning the mode of interaction of the histamine H2-agonist dimaprit.

H. Timmerman, E. Haaksma, G. M. Donné-op den Kelder, 1992, Journal of molecular graphics.

Serine and Threonine Residues Bend a-Helices in the x 1 5 g 2 Conformation

L. Pardo, J. Ballesteros, X. Deupí, 2000 .

An Interaction Model for Tiotidine and Analogues with the Histamine H2‐Receptor

H. Timmerman, E. Haaksma, H. Voss, 1992 .

In silico prediction of substrate properties for ABC-multidrug transporters.

G. Ecker, P. Ettmayer, E. Haaksma, 2008, Expert Opinion on Drug Metabolism & Toxicology.

Computer based screening of compound databases: 1. Preselection of benzamidine-based thrombin inhibitors

Thomas Fox, Eric E. J. Haaksma, T. Fox, 2000, J. Comput. Aided Mol. Des..

Factor Xa: Simulation studies with an eye to inhibitor design

Wilfred F. van Gunsteren, Xavier Daura, Eric E. J. Haaksma, 2000, J. Comput. Aided Mol. Des..

BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis

G. Adolf, N. Kraut, P. Garin‐Chesa, 2015, Molecular Cancer Therapeutics.